Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in adolescents with seasonal allergic rhinitis on background therapy
CTR20262478Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Keymed Biosciences. Started Aug 2026; status: active.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20262478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262478.